284 related articles for article (PubMed ID: 20307215)
21. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.
Mackensen F; Heinz C; Becker MD; Heiligenhaus A
Retina; 2008 Jan; 28(1):41-5. PubMed ID: 18185136
[TBL] [Abstract][Full Text] [Related]
22. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
24. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
Bakri SJ; Larson TA
Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema.
Avitabile T; Longo A; Reibaldi A
Am J Ophthalmol; 2005 Oct; 140(4):695-702. PubMed ID: 16226521
[TBL] [Abstract][Full Text] [Related]
28. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
29. Initial macular thickness and response to treatment in diabetic macular edema.
Soheilian M; Ramezani A; Yaseri M; Mirdehghan SA; Obudi A; Bijanzadeh B
Retina; 2011 Sep; 31(8):1564-73. PubMed ID: 21451442
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema.
Androudi S; Letko E; Meniconi M; Papadaki T; Ahmed M; Foster CS
Ocul Immunol Inflamm; 2005; 13(2-3):205-12. PubMed ID: 16019680
[TBL] [Abstract][Full Text] [Related]
31. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion.
Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1149-60. PubMed ID: 22331147
[TBL] [Abstract][Full Text] [Related]
32. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
33. Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema.
Jin E; Luo L; Bai Y; Zhao M
Ann Pharmacother; 2015 Apr; 49(4):387-97. PubMed ID: 25622852
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
Gokce G; Sobaci G; Durukan AH; Erdurman FC
Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
[TBL] [Abstract][Full Text] [Related]
35. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema.
Radwan AE; Arcinue CA; Yang P; Artornsombudh P; Abu Al-Fadl EM; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1801-6. PubMed ID: 23519884
[TBL] [Abstract][Full Text] [Related]
36. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
38. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
40. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion.
Kim JY; Park SP
Korean J Ophthalmol; 2009 Dec; 23(4):259-65. PubMed ID: 20046685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
